BRAF and non-small cell lung carcinoma: In addition, osimertinib, dabrafenib (BRAF inhibitor) and trametinib three-drug combination therapy reached a PFS of 7.4 months and 13.4 months in two NSCLC patients with BRAF V600E mutation-mediated resistance to osimertinib, respectively [92, 153].